Niagen Bioscience is trading at $2.53, up 6.84%, amid a broader market rebound after midterm results.
- No company-specific catalyst was confirmed for the November 4 move; the third-quarter report is scheduled after market close and does not explain the morning gain.
- Reuters reported U.S. futures rebounded as investors welcomed the prospect of divided government and reduced policy uncertainty. Biotech also rose, but Niagen Bioscience’s gain exceeded the sector move.